Cimetidine

CHEMBL30 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

252.3 g/mol

LogP

0.4

Phase

4

A first-generation H2 receptor antagonist that reduces gastric acid secretion by blocking histamine H2 receptors on parietal cells, used for peptic ulcer disease, gastroesophageal reflux disease, and pathological hypersecretory conditions. It is a potent inhibitor of several cytochrome P450 enzymes, leading to clinically significant drug interactions with many medications. It has largely been superseded by proton pump inhibitors for most acid-reducing indications.

น้ำหนักโมเลกุล

252.3400 g/mol

LogP

0.40

TPSA

114.00 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Generalized Anxiety Disorder Melanoma Gastroesophageal Reflux Disease Chronic Kidney Disease Breast Cancer Atopic Dermatitis Leukemia

กลไกการออกฤทธิ์

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

CN/C(=N\CCSCc1nc[nH]c1C)NC#N

InChI

InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)

Molecular Formula

C10H16N6S

HBD / HBA

3 / 4

พันธะที่หมุนได้

7

อะตอมหนัก

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A first-generation H2 receptor antagonist that reduces gastric acid secretion by blocking histamine H2 receptors on parietal cells, used for peptic ulcer disease, gastroesophageal reflux disease, and pathological hypersecretory conditions. It is a potent inhibitor of several cytochrome P450 enzymes, leading to clinically significant drug interactions with many medications. It has largely been superseded by proton pump inhibitors for most acid-reducing indications.

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Yes, Cimetidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL30. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2756. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Cimetidine บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C10H16N6S
คำพ้องความหมาย: 6

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.